NCT03960177 is a EARLY_PHASE1 clinical trial of Glucarpidase in Osteosarcoma, sponsored by OHSU Knight Cancer Institute.

Who is sponsoring NCT03960177?

NCT03960177 is sponsored by OHSU Knight Cancer Institute.

What drugs are being tested in NCT03960177?

Interventions in NCT03960177: Glucarpidase, Quality-of-Life Assessment.

What condition does NCT03960177 study?

NCT03960177 studies Osteosarcoma.

Is NCT03960177 still recruiting?

NCT03960177 is currently active, enrolled. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT03960177

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Active, enrolled EARLY_PHASE1 Last updated 7 January 2026

What this trial tests

EARLY_PHASE1 trial testing Glucarpidase in Osteosarcoma in 12 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 March 2019

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	OHSU Knight Cancer Institute
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	27 March 2019
Primary completion	31 December 2026
Estimated completion	31 December 2026
Sites	3 locations across United States

Drugs / interventions tested

Glucarpidase (GLUCARPIDASE) — full drug profile →
Quality-of-Life Assessment

Conditions studied

Osteosarcoma — all drugs for Osteosarcoma →

Sponsor

OHSU Knight Cancer Institute

Who can join

25 and older, any sex, with Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early phase I trial studies how well glucarpidase works in reducing toxicity in patients with osteosarcoma receiving high dose methotrexate treatment. Glucarpidase may reduce the levels of methotrexate in patients' blood and lead to shorter hospitalizations and a reduction in toxicities.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Rathore R, Van Tine BA. · · 2021 · cited 81× · PMID 33809018 · DOI 10.3390/jcm10061182

Verify or expand the search:

Other trials of Glucarpidase

Trials testing the same drug.

NCT05135858 — Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma · Phase 1 · unknown

Other recruiting trials for Osteosarcoma

Currently open trials in the same condition.

NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting

Other OHSU Knight Cancer Institute trials

Trials by the same sponsor.

NCT05453851 — A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatme · Phase 1, PHASE2 · not yet recruiting
NCT07511504 — Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanc · Phase 2 · not yet recruiting
NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
NCT07504835 — GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer · NA · not yet recruiting
NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03960177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OHSU Knight Cancer Institute
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03960177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing